SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ:SLNO) focused on whether Soleno and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have information that could assist in the Soleno investigation or if you are a Soleno investor who suffered a loss and would like to learn more, you can provide your information here:
https://www.rgrdlaw.com/cases-soleno-therapeutics-inc-investigation-slno.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
THE COMPANY: On March 26, 2025, Soleno announced that the U.S. Food and Drug Administration had approved VYKAT XR (diazoxide choline) extended-release tablets for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome.
THE REVELATION: On November 4, 2025, Soleno revealed during its quarterly earnings call that the discontinuation rate of VYKAT XR related to adverse effects was approximately 8% at the end of the third quarter of fiscal 2025. Soleno's CEO, Anish Bhatnagar, further admitted during the call that Soleno "did see a disruption in our [VYKAT XR] launch trajectory in the wake of a short seller report that was released in mid-August, mostly in the form of a lower number of start forms and increase discontinuations for non-serious adverse events." After this news, the price of Soleno shares fell more than 26%.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/slno-investigation-alert-investigation-launched-into-soleno-therapeutics-inc-attorneys-encourage-investors-and-potential-witnesses-to-contact-law-firm-302609148.html
SOURCE Robbins Geller Rudman & Dowd LLP
